These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 25031743)
1. Yes-associated protein (YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancer. Kim SK; Jung WH; Koo JS Int J Clin Exp Pathol; 2014; 7(6):3224-34. PubMed ID: 25031743 [TBL] [Abstract][Full Text] [Related]
2. Expression of Yes-associated protein (YAP) in breast phyllodes tumor. Kim SK; Jung WH; Koo JS Int J Clin Exp Pathol; 2014; 7(9):5997-6005. PubMed ID: 25337244 [TBL] [Abstract][Full Text] [Related]
3. Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues. Cao L; Sun PL; Yao M; Jia M; Gao H Hum Pathol; 2017 Oct; 68():166-174. PubMed ID: 28899737 [TBL] [Abstract][Full Text] [Related]
4. Expression of p16 and pRB in invasive breast cancer. Shin E; Jung WH; Koo JS Int J Clin Exp Pathol; 2015; 8(7):8209-17. PubMed ID: 26339389 [TBL] [Abstract][Full Text] [Related]
5. Differential expression of Yes-associated protein and phosphorylated Yes-associated protein is correlated with expression of Ki-67 and phospho-ERK in colorectal adenocarcinoma. Kim DH; Kim SH; Lee OJ; Huang SM; Kwon JL; Kim JM; Kim JY; Seong IO; Song KS; Kim KH Histol Histopathol; 2013 Nov; 28(11):1483-90. PubMed ID: 23673988 [TBL] [Abstract][Full Text] [Related]
6. Metaplastic carcinoma show different expression pattern of YAP compared to triple-negative breast cancer. Min Kim H; Kim SK; Jung WH; Koo JS Tumour Biol; 2015 Feb; 36(2):1207-12. PubMed ID: 25344213 [TBL] [Abstract][Full Text] [Related]
7. GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer. Arias-Pulido H; Royce M; Gong Y; Joste N; Lomo L; Lee SJ; Chaher N; Verschraegen C; Lara J; Prossnitz ER; Cristofanilli M Breast Cancer Res Treat; 2010 Aug; 123(1):51-8. PubMed ID: 19902352 [TBL] [Abstract][Full Text] [Related]
8. Implications of differences in expression of sarcosine metabolism-related proteins according to the molecular subtype of breast cancer. Yoon JK; Kim DH; Koo JS J Transl Med; 2014 May; 12():149. PubMed ID: 24884785 [TBL] [Abstract][Full Text] [Related]
9. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043 [TBL] [Abstract][Full Text] [Related]
10. Piwil2 is expressed in various stages of breast cancers and has the potential to be used as a novel biomarker. Liu JJ; Shen R; Chen L; Ye Y; He G; Hua K; Jarjoura D; Nakano T; Ramesh GK; Shapiro CL; Barsky SH; Gao JX Int J Clin Exp Pathol; 2010 Mar; 3(4):328-37. PubMed ID: 20490325 [TBL] [Abstract][Full Text] [Related]
11. Expression of Yes-associated protein (YAP) in metastatic breast cancer. Kim HM; Jung WH; Koo JS Int J Clin Exp Pathol; 2015; 8(9):11248-57. PubMed ID: 26617849 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Expression of Amine Oxidase Proteins in Breast Cancer. Sun WY; Choi J; Cha YJ; Koo JS Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29261141 [TBL] [Abstract][Full Text] [Related]
13. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer. Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243 [TBL] [Abstract][Full Text] [Related]
14. Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. Wu M; Wei W; Xiao X; Guo J; Xie X; Li L; Kong Y; Lv N; Jia W; Zhang Y; Xie X Med Oncol; 2012 Dec; 29(5):3240-9. PubMed ID: 22661383 [TBL] [Abstract][Full Text] [Related]
15. Correlation of expression of phosphorylated and non-phosphorylated Yes-associated protein with clinicopathological parameters in esophageal squamous cell carcinoma in a Korean population. Yeo MK; Kim SH; Kim JM; Huang SM; Kim MR; Song KS; Kim KH Anticancer Res; 2012 Sep; 32(9):3835-40. PubMed ID: 22993326 [TBL] [Abstract][Full Text] [Related]
16. Expression of autophagy-related markers beclin-1, light chain 3A, light chain 3B and p62 according to the molecular subtype of breast cancer. Choi J; Jung W; Koo JS Histopathology; 2013 Jan; 62(2):275-86. PubMed ID: 23134379 [TBL] [Abstract][Full Text] [Related]
17. Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Engstrøm MJ; Opdahl S; Hagen AI; Romundstad PR; Akslen LA; Haugen OA; Vatten LJ; Bofin AM Breast Cancer Res Treat; 2013 Aug; 140(3):463-73. PubMed ID: 23901018 [TBL] [Abstract][Full Text] [Related]
18. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery. Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768 [TBL] [Abstract][Full Text] [Related]
19. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients. Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313 [TBL] [Abstract][Full Text] [Related]
20. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis. Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]